» Articles » PMID: 27494024

Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy

Abstract

The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need to identify reliable outcome measures for young boys with DMD. The aim of this study was to develop a revised version of the North Star Ambulatory Assessment (NSAA) suitable for boys between the age of 3 and 5 years by identifying age appropriate items and revising the scoring system accordingly. Using the scale in 171 controls between the age of 2.9 and 4.8 years, we identified items that were appropriate at different age points. An item was defined as age appropriate if it was completed, achieving a full score, by at least 85% of the typically developing boys at that age. At 3 years (±3months) there were only 8 items that were age appropriate, at 3 years and 6 months there were 13 items while by the age of 4 years all 17 items were appropriate. A revised version of the scale was developed with items ordered according to the age when they could be reliably performed. The application of the revised version of the scale to data collected in young DMD boys showed that very few of the DMD boys were able to complete with a full score all the age appropriate items. In conclusion, our study suggests that a revised version of the NSAA can be used in boys from the age of 3 years to obtain information on how young DMD boys acquire new abilities and how this correlates with their peers.

Citing Articles

Evidentiary basis of the first regulatory qualification of a digital primary efficacy endpoint.

Servais L, Strijbos P, Poleur M, Mirea A, Butoianu N, Sansone V Sci Rep. 2024; 14(1):29681.

PMID: 39613806 PMC: 11606965. DOI: 10.1038/s41598-024-80177-9.


Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy.

Harper A, Topaloglu H, Mercuri E, Suslov V, Wu L, Ayanoglu C Sci Rep. 2024; 14(1):23488.

PMID: 39379403 PMC: 11461856. DOI: 10.1038/s41598-024-70783-y.


Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A Systematic Review.

Pascual-Morena C, Luceron-Lucas-Torres M, Martinez-Garcia I, Rodriguez-Gutierrez E, Patino-Cardona S, Sequi-Dominguez I Paediatr Drugs. 2024; 26(6):695-707.

PMID: 39331339 DOI: 10.1007/s40272-024-00655-5.


Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.

Rabbia M, Ormazabal M, Staunton H, Veenstra K, Eggenspieler D, Annoussamy M J Neuromuscul Dis. 2024; 11(3):701-714.

PMID: 38640165 PMC: 11091611. DOI: 10.3233/JND-230188.


Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease.

McDonald C, Camino E, Escandon R, Finkel R, Fischer R, Flanigan K J Neuromuscul Dis. 2024; 11(2):499-523.

PMID: 38363616 PMC: 10977441. DOI: 10.3233/JND-230219.


References
1.
Camp B, van Doorninck W, FRANKENBURG W, LAMPE J . Preschool developmental testing in prediction of school problems. Studies of 55 children in Denver. Clin Pediatr (Phila). 1977; 16(3):257-63. DOI: 10.1177/000992287701600309. View

2.
McDonald C, Henricson E, Abresch R, Florence J, Eagle M, Gappmaier E . The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013; 48(3):357-68. PMC: 3826053. DOI: 10.1002/mus.23905. View

3.
Connolly A, Florence J, Cradock M, Eagle M, Flanigan K, McDonald C . One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development. Pediatr Neurol. 2014; 50(6):557-63. PMC: 4197452. DOI: 10.1016/j.pediatrneurol.2014.02.006. View

4.
de Sanctis R, Pane M, Sivo S, Ricotti V, Baranello G, Frosini S . Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2014; 25(1):14-8. DOI: 10.1016/j.nmd.2014.09.015. View

5.
Piper M, Pinnell L, Darrah J, Maguire T, Byrne P . Construction and validation of the Alberta Infant Motor Scale (AIMS). Can J Public Health. 1992; 83 Suppl 2:S46-50. View